霍奇金淋巴瘤精准治疗策略

Precision therapeutic strategies for Hodgkin lymphoma

霍奇金淋巴瘤（HL）是一种罕见的B细胞恶性淋巴瘤类型,多发生于青年人.随着现代治疗技术的发展,约80%的患者可以被治愈.如何进一步提高HL的治愈率、使不良反应最小化是临床面临的新课题,近期有效率和远期生存率同样值得关注.文献报道疾病的分期对最佳治疗方案的选择至关重要.本文就有关HL的分期、早期治疗是否可以减少剂量、晚期治疗方案的选择及新药开发等问题进行讨论,以制定更精准的治疗策略,为临床提供参考.

Hodgkin lymphoma （HL） is a rare subtype of B-cell malignancies, and it often occurs in the youth. About 80 % patients can be cured with the advance of modern therapy. How to further improve the cure rate of HL and minimize adverse reactions are new tasks faced by the clinicians, meanwhile, short-term curative effect and long-term survival rate are worthy of attention. An accurate assessment of disease stage is crucial for the selection of the appropriate therapy. This review discusses the hot issues regarding HL treatments to further improve the precision therapeutics, and to provide more references for clinical treatment.